TScan CFO granted 350,000 stock options

TScan Therapeutics granted Chief Financial Officer Jason Amello a stock option for 350,000 shares of voting common stock on January 20, 2026.

Rhea-AI Filing Summary

TScan Therapeutics granted Chief Financial Officer Jason Amello a stock option for 350,000 shares of voting common stock on January 20, 2026. The option has an exercise price of $1.12 per share and was awarded at no cost to the executive. Following this grant, Amello beneficially owns options for 350,000 shares.

The award vests over time: 25% of the shares vest on the one-year anniversary of January 20, 2026, with the remaining 75% vesting in equal monthly installments over the next 36 months, conditioned on his continued service with the company.

Insider Trade Summary

Grant/Award: 350,000 shares

Grant/Award 1 txn

Insider Amello Jason

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	350,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 350,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TScan Therapeutics (TCRX) report in this Form 4?

The company reported a grant of a stock option giving Chief Financial Officer Jason Amello the right to purchase 350,000 shares of voting common stock.

What is the exercise price of the new stock option granted to the TScan (TCRX) CFO?

The stock option granted to the CFO has an exercise price of $1.12 per share for voting common stock.

How many TScan (TCRX) shares underlie the CFO’s new stock option?

The option covers 350,000 shares of TScan Therapeutics voting common stock, all reported as beneficially owned following the transaction.

What is the vesting schedule for the TScan (TCRX) CFO stock option granted on January 20, 2026?

The option vests 25% on the one-year anniversary of January 20, 2026, with the remaining 75% vesting in equal monthly installments over the next 36 months, subject to continued service.

When does the TScan (TCRX) CFO stock option expire?

The stock option granted to the CFO expires on January 20, 2036, as disclosed in the derivative securities table.

Is the TScan (TCRX) CFO’s new stock option held directly or indirectly?

The Form 4 shows the CFO’s 350,000-share stock option is held with direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/22/2026 - 05:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Amello Jason

(Last) (First) (Middle)

C/O TSCAN THERAPEUTICS, INC.

830 WINTER STREET

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TScan Therapeutics, Inc. [ TCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.12	01/20/2026		A		350,000		(1)	01/20/2036	Voting Common Stock	350,000	$0.00	350,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date.

	/s/ Zoran Zdraveski, Attorney-in-Fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.